Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria.

Author information

Affiliations

  • 1. Department of Hematology and Medical Oncology, Winship Cancer Institute, and Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
      Authors
    • Galipeau J 1
    (1 author)
  • 2. Section of Hematology, Stem Cell Research Laboratory and Cell Factory, Department of Medicine, University of Verona, Policlinico G.B. Rossi, P.le L.A., Italy.
      Authors
    • Krampera M 2
    (1 author)

ORCIDs linked to this article

Cytotherapy, 01 Feb 2015, 17(2):125-127
https://doi.org/10.1016/j.jcyt.2014.12.008 PMID: 25593076 

This is a comment on "Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications." Cytotherapy. 2015 Feb;17(2):128-39.

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.jcyt.2014.12.008

References 

Articles referenced by this article (10)

Citations & impact 

Impact metrics

43
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (43) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.